Abstract 376O
Background
There is no multicenter clinical study about cytokine-induced killer (CIK) cells in lung cancer. This randomized, multicenter trial was designed to evaluate the efficacy of CIK cell immunotherapy combination with chemotherapy in patients with advanced squamous non-small-cell lung cancer (NSCLC).
Methods
In this phase II trial, 90 patients with untreated, stage IIIB/IV squamous NSCLC were randomized to autologous CIK cell immunotherapy plus gemcitabine and cisplatin (CIK-CT group, n = 45), or gemcitabine and cisplatin (CT group, n = 45). The primary endpoint was progression-free survival (PFS) and secondary endpoint was overall survival (OS) evaluated by Kaplan–Meier analyses and treatment hazard ratios (HRs) with the Cox proportional hazards model.
Results
After a median follow-up of 29.3 months, the median PFS was 8.7 months (95% CI, 7.1 to 10.3) in the CIK-CT group and 4.0 months (95% CI, 3.1 to 5.0) in the CT group (HR, 0.26; 95% CI, 0.16 to 0.43; P < .001). The median OS was 21.0 months (95% CI, 17.8 to 24.2) in the CIK-CT group and 10.3 months (95% CI, 7.9 to 12.1) in the CT group (HR, 0.22; 95% CI, 0.13 to 0.40; P < .001). The objective response rate was 62.2% (95% CI, 47.9% to 76.5%) in the CIK-CT group and 31.1% (95% CI, 17.4% to 44.8%) in the CT group (P < .001). The adverse events of grade 3 or higher were 33.3% and 42.2% in the CIK-CT group and CT group, respectively.
Conclusions
These data suggested that the addition of CIK cell immunotherapy to chemotherapy resulted in significantly longer PFS and OS than chemotherapy alone in patients with previously untreated, advanced squamous NSCLC.
Clinical trial identification
NCT01631357.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Key Technologies R&D Program of China grant Awards No. 2015BAI12B12 (to Xiubao Ren).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
375O - Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC
Presenter: Makoto Nishio
Session: Proffered paper session on Thoracic cancers
Resources:
Abstract
Webcast
377O - A randomized double-blind phase III study of niraparib versus placebo as maintenance therapy in extensive-stage small cell lung cancer
Presenter: Xinghao Ai
Session: Proffered paper session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
LBA4 - GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
Presenter: Caicun Zhou
Session: Proffered paper session on Thoracic cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts LBA4 and 375O
Presenter: Martin Reck
Session: Proffered paper session on Thoracic cancers
Resources:
Slides
Webcast
Invited Discussant abstracts 376O and 377O
Presenter: Anne-Marie Dingemans
Session: Proffered paper session on Thoracic cancers
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Linda Coate
Session: Proffered paper session on Thoracic cancers
Resources:
Webcast
LIVE Q&A
Presenter: Linda Coate
Session: Proffered paper session on Thoracic cancers
Resources:
Webcast